Future longitudinal studies with larger cohorts are warranted to confirm these results, explore the mechanistic link between ATF4-TLR4 signaling and hepatic fibrosis, and evaluate the response of these markers to therapeutic interventions (e.g., weight loss, insulin sensitizers, or anti-inflammatory agents). This evidence concerns the gene INS and Hepatic fibrosis.